Placebo Medication and Sham Surgery Responses in Benign Prostatic Hyperplasia Treatments: Implications for Clinical Trials

Overview

Journal Curr Urol Rep

Publisher Current Science

Specialty Urology

Date 2015 Aug 26

PMID 26303775

Citations 5

Authors

Igor Sorokin

Adam Schatz

Charles Welliver

Affiliations

Soon will be listed here.

Abstract

Placebo medications and sham surgeries have long been thought to be inert treatments. These groups served as a threshold to which an active treatment should be compared in a randomized trial to determine the true efficacy of the active treatment. However, surprising changes in subjective symptom scores and objective measures of voiding have been demonstrated in numerous placebo medication or sham surgery arms of trials. The exact mechanisms by which these inactive treatments augment patient outcomes are not clearly defined and multiple theories have been proposed to explain the often pronounced response. It appears that urologic outcomes are particularly prone to these effects and the astute physician should keep these responses in mind when interpreting any trial on a new therapy.

Citing Articles

The placebo and nocebo effects in functional urology.

Mostafaei H, Jilch S, Carlin G, Mori K, Quhal F, Pradere B Nat Rev Urol. 2021; 19(3):171-189.

PMID: 34949831 DOI: 10.1038/s41585-021-00545-2.

Placebo Effects in Traumatic Brain Injury.

Polich G, Iaccarino M, Kaptchuk T, Morales-Quezada L, Zafonte R J Neurotrauma. 2018; 35(11):1205-1212.

PMID: 29343158 PMC: 6016098. DOI: 10.1089/neu.2017.5506.

Open-label versus double-blind placebo treatment in irritable bowel syndrome: study protocol for a randomized controlled trial.

Ballou S, Kaptchuk T, Hirsch W, Nee J, Iturrino J, Hall K Trials. 2017; 18(1):234.

PMID: 28545508 PMC: 5445390. DOI: 10.1186/s13063-017-1964-x.

Informed consent and clinical trials: where is the placebo effect?.

Blease C, Bishop F, Kaptchuk T BMJ. 2017; 356:j463.

PMID: 28159769 PMC: 6888513. DOI: 10.1136/bmj.j463.

Two-year results after convective radiofrequency water vapor thermal therapy of symptomatic benign prostatic hyperplasia.

Dixon C, Cedano E, Pacik D, Vit V, Varga G, Wagrell L Res Rep Urol. 2016; 8:207-216.

PMID: 27921028 PMC: 5123707. DOI: 10.2147/RRU.S119596.

References

Bdesha A, Bunce C, Kelleher J, Snell M, Vukusic J, Witherow R . Transurethral microwave treatment for benign prostatic hypertrophy: a randomised controlled clinical trial. BMJ. 1993; 306(6888):1293-6. PMC: 1677744. DOI: 10.1136/bmj.306.6888.1293. View

Roehrborn C, Preminger G, Newhall P, Denstedt J, Razvi H, Chin L . Microwave thermotherapy for benign prostatic hyperplasia with the Dornier Urowave: results of a randomized, double-blind, multicenter, sham-controlled trial. Urology. 1998; 51(1):19-28. DOI: 10.1016/s0090-4295(97)00571-2. View

Sech S, Montoya J, Bernier P, Barnboym E, Brown S, Gregory A . The so-called "placebo effect" in benign prostatic hyperplasia treatment trials represents partially a conditional regression to the mean induced by censoring. Urology. 1998; 51(2):242-50. DOI: 10.1016/s0090-4295(97)00609-2. View

Walach H, Sadaghiani C, Dehm C, Bierman D . The therapeutic effect of clinical trials: understanding placebo response rates in clinical trials--a secondary analysis. BMC Med Res Methodol. 2005; 5:26. PMC: 1201145. DOI: 10.1186/1471-2288-5-26. View

Andersen M, Dahlstrand C, Hoye K . Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia. Eur Urol. 2000; 38(4):400-9. DOI: 10.1159/000020315. View

Maria G, Brisinda G, Civello I, Bentivoglio A, Sganga G, Albanese A . Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology. 2003; 62(2):259-64; discussion 264-5. DOI: 10.1016/s0090-4295(03)00477-1. View

Elhilali M, Pommerville P, Yocum R, Merchant R, Roehrborn C, Denmeade S . Prospective, randomized, double-blind, vehicle controlled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasia. J Urol. 2012; 189(4):1421-6. PMC: 3740739. DOI: 10.1016/j.juro.2012.11.003. View

Na Y, Ye Z, Zhang S . Efficacy and safety of dutasteride in Chinese adults with symptomatic benign prostatic hyperplasia: a randomized, double-blind, parallel-group, placebo-controlled study with an open-label extension. Clin Drug Investig. 2011; 32(1):29-39. DOI: 10.2165/11593750-000000000-00000. View

Byrnes C, MORTON A, Liss C, Lippert M, GILLENWATER J . Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: a community based study. CUSP Investigators. Community based study of Proscar. Clin Ther. 1995; 17(5):956-69. DOI: 10.1016/0149-2918(95)80073-5. View

10.

Welliver C, Kottwitz M, Feustel P, McVary K . Clinically and Statistically Significant Changes Seen in Sham Surgery Arms of Randomized, Controlled Benign Prostatic Hyperplasia Surgery Trials. J Urol. 2015; 194(6):1682-7. DOI: 10.1016/j.juro.2015.06.091. View

11.

Lepor H . Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. Urology. 1998; 51(6):901-6. DOI: 10.1016/s0090-4295(98)00127-7. View

12.

McVary K, Roehrborn C, Avins A, Barry M, Bruskewitz R, Donnell R . Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011; 185(5):1793-803. DOI: 10.1016/j.juro.2011.01.074. View

13.

Madersbacher S, Marszalek M, Lackner J, Berger P, Schatzl G . The long-term outcome of medical therapy for BPH. Eur Urol. 2007; 51(6):1522-33. DOI: 10.1016/j.eururo.2007.03.034. View

14.

Roehrborn C, Nickel J, Andriole G, Gagnier R, Black L, Wilson T . Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial. Urology. 2011; 78(3):641-6. DOI: 10.1016/j.urology.2011.03.063. View

15.

Marks L, Gittelman M, Hill L, Volinn W, Hoel G . Rapid efficacy of the highly selective α(1A)-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol. 2012; 189(1 Suppl):S122-8. DOI: 10.1016/j.juro.2012.11.020. View

16.

McVary K, Roehrborn C, Kaminetsky J, Auerbach S, Wachs B, Young J . Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2007; 177(4):1401-7. DOI: 10.1016/j.juro.2006.11.037. View

17.

Roehrborn C, McVary K, Elion-Mboussa A, Viktrup L . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol. 2008; 180(4):1228-34. DOI: 10.1016/j.juro.2008.06.079. View

18.

Roehrborn C, Oesterling J, Auerbach S, Kaplan S, Lloyd L, Milam D . The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. Urology. 1996; 47(2):159-68. DOI: 10.1016/s0090-4295(99)80409-9. View

19.

Kaplan S, Roehrborn C, Rovner E, Carlsson M, Bavendam T, Guan Z . Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA. 2006; 296(19):2319-28. DOI: 10.1001/jama.296.19.2319. View

20.

Stoner E . Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology. 1994; 43(3):284-92; discussion 292-4. DOI: 10.1016/0090-4295(94)90068-x. View